Compare TUSK & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | TTRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.7M | 107.2M |
| IPO Year | 2016 | N/A |
| Metric | TUSK | TTRX |
|---|---|---|
| Price | $3.33 | $5.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 437.1K | 57.9K |
| Earning Date | 05-11-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $44,292,000.00 | N/A |
| Revenue This Year | $383.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $2.57 |
| 52 Week High | $3.92 | $6.75 |
| Indicator | TUSK | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 55.42 |
| Support Level | $2.09 | $3.92 |
| Resistance Level | $3.54 | $5.55 |
| Average True Range (ATR) | 0.29 | 0.59 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 37.09 | 41.24 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.